Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III similarity study of GB222 plus chemotherapy versus bevacizumab plus chemotherapy in advanced non-squamous NSCLC
ChiCTR-IIR-17013100Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of GB222 and bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Nov 2017; status: recruiting.
02
Drugs
GB222bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-17013100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013100.